Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11026 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Anastasilakis, A. D., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Makras P. (2019).  Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.. J Bone Miner Res.
Anastasilakis, A. D., Polyzos S. A., & Nikolopoulos P. (2008).  Subendothelial carotid hematoma after fine-needle aspiration biopsy of a solitary thyroid nodule.. J Ultrasound Med. 27(10), 1517-20.
Anastasilakis, A. D., Polyzos S. A., Tsoli M., Papatheodorou A., Kokkoris P., Kaltsas G., et al. (2017).  Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity.. Metabolism. 71, 198-201.
Anastasilakis, A. D., Makras P., Doulgeraki A., Polyzos S. A., Guarnieri V., & Papapoulos S. E. (2021).  Denosumab for the treatment of primary pediatric osteoporosis.. Osteoporos Int.
Anastasilakis, A. D., Polyzos S. A., Rodopaios N. E., Makras P., Kumar A., Kalra B., et al. (2022).  Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study.. Metabolism. 141, 155397.
Anastasilakis, A. D., Makras P., Paccou J., Bisbinas I., Polyzos S. A., & Papapoulos S. E. (2023).  Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab.. J Clin Med. 12(18), 
Anastasilakis, A. D., Koulaxis D., Kefala N., Polyzos S. A., Upadhyay J., Pagkalidou E., et al. (2017).  Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD. Metabolism. 73, 1-8.
Anastasilakis, A. D., Ruggeri R-M., Polyzos S. A., Makras P., Molyva D., Campennì A., et al. (2013).  Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature.. Metabolism. 62(10), 1350-6.
Anastasilakis, A. D., Tournis S., Yavropoulou M. P., Polyzos S. A., & Makras P. (2018).  Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. Calcif Tissue Int. 103(1), 107-108.
Anastasilakis, A. D., Polyzos S. A., Savvidis M., Anastasilakis D. A., Sarridimitriou A., Kumar A., et al. (2023).  Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study.. Endocrine. 81(3), 573-578.
Anastasilakis, A. D., Toulis K. A., Nisianakis P., Goulis D. G., Kampas L., Valeri R-M., et al. (2012).  Selenomethionine treatment in patients with autoimmune thyroiditis: a prospective, quasi-randomised trial.. Int J Clin Pract. 66(4), 378-83.
Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Ballaouri I., Efstathiadou Z., et al. (2009).  No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.. Clin Endocrinol (Oxf). 70(4), 522-6.
Anastasilakis, A. D., Toulis K. A., Polyzos S. A., Anastasilakis C. D., & Makras P. (2012).  Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab.. Ther Clin Risk Manag. 8, 295-306.
Anastasilakis, A. D., Polyzos S. A., Skouvaklidou E. C., Kynigopoulos G., Saridakis Z. G., Apostolou A., et al. (2016).  Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans.. Metabolism. 65(10), 1459-65.
Anastasilakis, A. D., Polyzos S. A., Anastasilakis C. D., Toulis K. A., & Makras P. (2011).  Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesis.. Med Hypotheses. 77(1), 109-11.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Ntenti C., Mandanas S., & Makras P. (2021).  Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.. Endocrine.
Anastasilakis, A. D., Polyzos S. A., Avramidis A., Toulis K. A., Papatheodorou A., & Terpos E. (2010).  The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.. Clin Endocrinol (Oxf). 72(6), 752-7.
Anastasilakis, A. D., Polyzos S. A., Makras P., Douni E., & Mantzoros C. S. (2019).  Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. Metabolism. 93, 100-102.
Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Koukoulis G., Kita M., et al. (2008).  Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.. Horm Metab Res. 40(4), 281-5.
Anastasilakis, A. D., Papachatzopoulos S., Makras P., Gkiomisi A., Nikolakopoulos P., Polyzos S. A., et al. (2022).  The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis.. Bone. 158, 116354.
Anastasilakis, A. D., Tsourdi E., Makras P., Polyzos S. A., Meier C., McCloskey E. V., et al. (2019).  Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society.. Bone. 127, 401-418.
Anastasilakis, A. D., Polyzos S. A., Efstathiadou Z. A., Savvidis M., Sakellariou G. T., Papatheodorou A., et al. (2015).  Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.. Metabolism. 64(10), 1291-7.
Anastasilakis, D. A., Makras P., Polyzos S. A., & Anastasilakis A. D. (2019).  Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview.. Hormones (Athens). 18(1), 65-70.
Anastasilakis, A. D., Polyzos S. A., & Makras P. (2018).  THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.. Eur J Endocrinol. 179(1), R31-R45.
Anastasilakis, A. D., Trovas G., Balanika A., Polyzos S. A., Makras P., & Tournis S. (2020).  Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.. J Clin Densitom.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές